Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (scDiabody-CH3) is a fusion protein of two scDiabodies connected together by a CH3 region. In single-chain Diabodies, an additional connecting linker is introduced between chains of the anti-CD37/anti-CD64 diabody. The scDiabody with two specificities is fused to each of the CH3 chains to extend half-life. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Non-Hodgkin's lymphoma (NHL); Diffuse large B cell lymphoma (DLBCL); Chronic lymphocytic leukemia (CLL) therapy.